Navigation Links
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Date:8/5/2008

r oral administration. Preclinical studies also indicate that CR845 possesses anti-itch properties. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing, or elicit signs of addiction in animal models. CR845 and related compounds are covered by a recently issued U.S. patent.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates within multiple classes of peripherally-acting analgesics. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreen(TM) technology.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Cara's research and clinical studies and Cara's ability to obtain additional financing. These forward-looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
7. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
8. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  The University of Maryland,s A. James ... groundbreaking of the new A. James Clark Hall at ... will cultivate transformative new engineering and biomedical technologies to ... at 10:00 a.m. on November 21 at the site ... Lot, adjacent to the Jeong H. Kim Engineering Building, ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... PLAINFIELD, N.J. , Nov. 21, 2014  PTC Therapeutics, ... that the 2014 Legend of Technology Award for Vision, Innovation, ... , Ph.D., Chief Executive Officer. This award recognizes an individual ... in New Jersey for several decades. ... of Technology Award," stated Stuart Peltz , Ph.D., CEO ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
(Date:11/23/2014)... Tbdress.com has recently announced that its Special Friday ... The special offer will provide ladies many gorgeous shoes at ... world’s largest women’s dresses retailers, and its shoes include many ... discounts on that day: Everything at Tbdress.com is up to ... $89). , People can use the following coupon codes as ...
(Date:11/23/2014)... NY (PRWEB) November 23, 2014 ... allege heart attacks, strokes, deep vein thrombosis and ... in a federal multidistrict litigation (MDL) underway in ... reports. , Court documents updated on November ... Litigation (JPML) show the filing of 259 lawsuits ...
(Date:11/23/2014)... Nov. 23, 2014 (HealthDay News) -- The holidays can ... because sensory overload can trigger major meltdowns, an expert ... the best of circumstances, but when you have children ... Gibbs, an occupational therapy professor at University of the ... "It,s best to let your hosts or visitors ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 23, 2014 ... the market such as its significance, programs and ... globally and Chinese suppliers major market gamers in ... company information, item specifications, prospective, manufacturing value, and ... statistical research, the evaluation symbolizes the globally and ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 SWAccessControl.com's high ... global market. Recently, the company has announced its new ... special offer on these high quality power suppliers. All ... 30% off. The special offer lasts until Dec. 20, ... many of them have been supporting it for a ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
... State University biologist continue to collaborate with the Harvard ... of a certain cellular process that can play a ... K-State associate professor in the Division of Biology, received ... Institute of General Medical Sciences through Recovery Act funding. ...
... 21 One in eight women will be diagnosed with breast cancer ... common type of cancer among women in the United States. Early detection ... one diagnosis is 98 percent. Stage two still has a very high ... the story here: http://www.mediaseed.tv/Story.aspx?story=37000 , , ...
... LONDON, Sept. 21 /PRNewswire-FirstCall/ - Equity Capital ... a preliminary review of the HTDS business ... to all HTDS followers at the following ... Management PLC, (ECM) believes that in the ...
... , KANSAS CITY, Mo., Sept. 21 Public ... recommend seasonal influenza vaccination as the first line of defense this ... The American Lung Association of the Central States is kicking ... City and is supporting local public health efforts to get Greater ...
... , , BEDFORD, Mass., Sept. ... their "Passion & Results" Award. The winners were presented with ... International Society on Thrombosis and Haemostasis (ISTH) held in Boston, MA, ... for Clinical Chemistry (AACC), in Chicago, IL, July 19-23. ...
... from dementia , MONDAY, Sept. 21 (HealthDay News) -- ... pace, and by next year 35.6 million people around the ... since 2005, a new report predicts. , Incidence of ... in 2030 and 115.4 million in 2050, according to ...
Cached Medicine News:Health News:Equity Capital Management H1N1 Vaccines and Hard to Treat Diseases (HTDS) 2Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 2Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 3Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 4Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 5Health News:Instrumentation Laboratory Announces 'Passion & Results' Award Winners 2Health News:Instrumentation Laboratory Announces 'Passion & Results' Award Winners 3Health News:Instrumentation Laboratory Announces 'Passion & Results' Award Winners 4Health News:Alzheimer's Soars, Global Focus Needed: Study 2Health News:Alzheimer's Soars, Global Focus Needed: Study 3
Soft yet durable, these single-patient use pads are designed to have the quality look of reusable pads but provide the hygienic advantages of disposability....
The lower body blanket is designed to be used primarily during surgery on the upper half of the body....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: